Lakeland Ledger - Lakeland,FL,USA
... The Cambridge-based firm won federal approval to resume sales of a multiple sclerosis drug, Tysabri, that was pulled from the market in February 2005 because ...
Multiple Sclerosis News
4. | What treatments are you currently receiving or have you received in the past? | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Kaiser held in contempt Contra Costa Times Tue, 26 Dec 2006 3:03 AM PST Oakland hospital hasn't made sufficient progress on terms of consent decree to be more accessible to the disabled. Post a Comment |
Caregiving takes toll on men NorthJersey.com Sun, 24 Dec 2006 9:54 PM PST WEST CHESTER, Pa. -- Joe Wolf still remembers his wife, Joanne, as a healthy 18-year-old with long brown hair and a '61 Chevy. They met through a social group at a Presbyterian church. They got married and had two children. |
Stakeholder Insight: Multiple Sclerosis - Disease-modifying efficacy and side effects guide treatment choice Pharmaceutical Business Review Wed, 20 Dec 2006 10:47 PM PST Introduction The disease-modifying drugs are considered by physicians to represent a significant advance for the management of MS. However, none is fully effective and there are problems with regards to side effects, dosing regimens and cost. |
Vitamin D May Reduce Risk of MS, Study Says RedNova Thu, 21 Dec 2006 6:06 AM PST Researchers have found new evidence that people with higher blood levels of vitamin D have a reduced risk for developing multiple sclerosis. MS is thought to be an autoimmune disease, meaning that it causes the body's own immune system cells to turn against some healthy part of the body. |
Study finds people with higher Vitamin D levels less likely to develop MS San Antonio Express News Wed, 20 Dec 2006 3:31 PM PST Vitamin D is called the "sunshine" vitamin. Much of the Vitamin D circulating in your body right now comes from the sun. A new study published in Wednesday's "Journal of the American Medical Association" found people with the highest levels of Vitamin D were 62 percent less likely to develop multiple sclerosis, a chronic nerve-damaging disease. |
Vitamin D May Protect Against MS MedicineNet.com Wed, 20 Dec 2006 12:37 PM PST Title: Vitamin D May Protect Against MS Category: Health News Created: 12/20/2006 Last Editorial Review: 12/20/2006 |
REMYELINATION EXTENSIVE IN SUBSET OF THOSE WITH MS
A study by an international team of collaborators suggests that a substantial amount of natural remyelination can occur in people with MS. While previous studies had shown natural myelin repair in people with MS, this study found evidence of extensive myelin repair - not only in patients with relapsing MS, but also in a subset of patients with progressive disease.
The investigators examined completely remyelinated lesions (so-called shadow plaques) or partially remyelinated lesions (shadow plaque areas) in 51 autopsies of patients with different clinical courses and disease durations.
In about 20 percent of patients' brains studied, remyelination was extensive, not only in those with a relapsing course, but also in those with progressive disease. The extent of remyelination was variable. In 20% of the patients, the extent of remyelination was extensive, with 60-96% of the global lesion area remyelinated. Longer disease duration and older age at death were associated with more extensive remyelination. No link was found between the extent of repair and the age at onset, gender or type of MS.
Further research is needed to determine why some individuals show highly efficient myelin repair while others do not. These study results indicate that the variable and individual extent of remyelination must be considered in the design of future clinical trials seeking to promote CNS repair.
Center for Brain Research, Medical University of Vienna, Vienna, Austria
ONLINE EDUCATION FOR THOSE WITH MS
The Expert MS Patient, online at http://www.expertmspatient.com, is an educational tool that addresses your specific needs.
The site, created by the Consortium of MS Centers (CMSC) and the International Organization of MS Nurses (IOMSN), offers:
· Video programs, featuring CMSC and IOMSN members, addressing relevant MS topics. Transcripts of these topics will also be available.
· A searchable online database of Frequently Asked Questions (FAQs).
· An opportunity for you to ask questions, which will be answered by nurses, doctors, and therapists who specialize in MS care.
An advisory board, composed of CMSC and IOMSN members, reviews all material on the site.
MBP8298 HOLDS PROMISE FOR PROGRESSIVE MS
Following the sixth meeting of the independent Data Safety Monitoring Board, (which provides objective, independent safety monitoring of clinical trials) BioMS has received a recommendation to continue its pivotal phase II/III clinical trial for MBP8298 for the treatment of secondary progressive MS.
This was the sixth of several regularly scheduled reviews by the Data Safety Monitoring Board. The pivotal phase II/III study is now ongoing at trial sites across Canada and Europe.
Results of the Phase II and long-term follow-up treatment of progressive MS patients with MBP8298, which were published in the European Journal of Neurology, show that MBP8298 safely delayed disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes.
Treatment and follow-up in patients in this DR2 and DR4 responder group - who comprise up to 75% of MS patients - had a median time to disease progression of 78 months as compared to 18 months for patients who received placebo.
"Our data suggest that we can safely delay progression of MS in an identified responder group of patients for extended periods of time," said Ingrid Catz, co-inventor of the drug and co-author of the Phase II study. "Recognizing the high variability of the disease in MS patients, the clinical and mechanistic evidence gathered to date supports the rationale of targeting patients with the HLA-DR2 or HLA-DR4 immune response gene. The identification of this responder group will improve efficiency toward the achievement of objectives in future clinical trials with MBP8298, while the potential for clinical responses in patients with other HLA haplotypes is further explored."
MBP8298 is a synthetic Myelin Basic Protein peptide (MBP) comprised of 17 amino acids. Administered as an intravenous injection, five minutes or less in duration, every six months, the drug is expected to induce immunological tolerance specific to the injected antigen.
"MBP8298 appears to have a mechanism of action somewhat like glatiramer acetate (Copaxone)," explains MSF Medical Advisor Ben Thrower, M.D. "Copaxone was designed to look like myelin basic protein and works by shifting the immune system to a less inflammatory state. MBP8298 appears to work in a similar fashion."
While these results are positive, they must be confirmed in the ongoing Phase III trial. To learn more, visit http://www.biomsmedical.com.
Vitamin D may cut multiple sclerosis risk, study finds Reuters via Yahoo! News Tue, 19 Dec 2006 1:57 PM PST People with higher levels of vitamin D have a markedly reduced risk of developing multiple sclerosis (MS), according to a study published on Tuesday that may point to a promising way to protect against the disease. |
Vitamin D May Lower Risk of Multiple Sclerosis in Whites Health Scout Tue, 19 Dec 2006 5:12 PM PST WEDNESDAY, Dec. 20 (HealthDay News) -- Could getting some extra sunshine help prevent the development of multiple sclerosis? |
Vitamin D May Lower Risk of Multiple Sclerosis, Study Finds RedNova Wed, 20 Dec 2006 4:20 AM PST By Kathleen Fackelmann Vitamin D might help protect people from developing multiple sclerosis, an incurable disease of the central nervous system, a study reports today. |
Higher levels of vitamin D in the blood may lower risk of multiple sclerosis EurekAlert! Tue, 19 Dec 2006 1:10 PM PST New research suggests that having higher circulating levels of vitamin D is associated with a reduced risk for multiple sclerosis, although this relationship was not seen for black and Hispanic individuals, according to a study in the December 20 issue of JAMA. |
Schoolgirl Raises Jd2,000 for Multiple Sclerosis Patients RedNova Tue, 19 Dec 2006 1:50 PM PST According to "Jordan Times", a 15-year-old girl single-handedly raised more than JD2,000 for patients diagnosed with multiple sclerosis (MS). |
Vitamin D May Lower Risk of Multiple Sclerosis in Whites KOLD News 13 Tuscon Tue, 19 Dec 2006 2:49 PM PST By Serena Gordon , HealthDay Reporter WEDNESDAY, Dec. 20 (HealthDay News) -- Could getting some extra sunshine help prevent the development of multiple sclerosis?... |
High Levels of Vitamin D In the Body May Decrease the Risk of Multiple Sclerosis Newswise Tue, 19 Dec 2006 2:28 PM PST In the first large-scale, prospective study to investigate the relationship between vitamin D levels and MS, researchers at the Harvard School of Public Health (HSPH) have found an association between higher levels of vitamin D in the body and a lower risk of MS. |
2006 - A Very Good Year in MS Research
PR Newswire (press release) - New York,NY,USA
... The FDA approved the return to market of Tysabri(R)
(natalizumab ... Since Tysabri's return to market last summer
there have been no new cases of PML reported. ...
MS drug unlikely to gain OK for Crohn's
Boston Globe - United States
... executive, James Mullen, says the Cambridge biotechnology
company is unlikely to receive approval from European regulators
to use its drug Tysabri to treat ...
See all stories on this topic
Dismay over MS treatment decision
BBC News - UK
Both the MS Society and the MS Trust believe the drug
Tysabri could help slow the progression of disability in hundreds
of sufferers. ...
See all stories on this topic
Monday's Analysts' Upgrades and Downgrades
TheStreet.com - USA
... Stock is up 15% since the strong third quarter earnings report.
Tysabri also unlikely to see accelerated sales in the near-term,
based on channel checks. ...
Acordia Plans Added Trial
TheStreet.com - USA
Acorda Therapeutics (ACOR - commentary - Cramer's Take) plans an additional Phase 3 trial of its Fampridine-SR drug in people with multiple sclerosis. ...
Acorda to conduct additional MS drug trial
BusinessWeek - USA
In September 2006, the company said its Fampridine-SR MS drug improved the ... completed under a Special Protocol Assessment with the FDA, meaning Acorda sat down ...
Acorda Calls for 2 More Trials
Motley Fool - USA
... On Friday, Acorda updated investors on the progress of its MS drug, named Fampridine-SR. As expected, the FDA is requiring another ...
UPDATE1-Acorda to conduct additional Phase III trial for MS drug
Reuters - USA
... In September, the company had reported positive data from its earlier late-stage trial of the drug, Fampridine-SR. Acorda Therapeutics said the FDA requires ...
Market Report -- In Play (ACOR)
MSN Money - USA
Acorda Therapeutics announces it will design and conduct an additional Phase 3 trial of Fampridine-SR in people with MS Co confirmed that, based on feedback it ...
This 30 year old male had a week of visual blurring described as "milkiness" involving the left eye at the age of 13 years. At 24, he experienced numbness and tingling in both legs and stumbling gait. MR images show high signal in periatrial white matter on T2-weighted images, and low signal on T1 pre- and post gadolinium. These findings are typical of the non-acute plaques seen in MS. There is very little enhancement with gadolinium. The lateral ventricles are somewhat enlarged. Most of the lesion burden is in white matter, but, as seen at a higher level, grey matter is also involved. | |||
|
Mary Godleski / AP file |
An abundance of vitamin D seems to help prevent multiple sclerosis, according to a study in more than 7 million people that offers some of the strongest evidence yet of the power of the “sunshine vitamin” against MS.
The research found that white members of the U.S. military with the highest blood levels of vitamin D were 62 percent less likely to develop multiple sclerosis than people with low levels.
There was no such connection in blacks or Hispanics, possibly because there were so few in the group studied. Also, the body makes vitamin D from sunlight, and the pigmented skin of blacks and other dark-skinned ethnic groups doesn’t absorb sunlight as easily as pale skin.
“This is the first large prospective study where blood levels are measured in young adults and compared to their future risk. It’s definitely different and much stronger evidence,” said Dr. Alberto Ascherio, the senior author and an associate professor of nutrition at Harvard’s School of Public Health.
The study appears in Wednesday’s Journal of the American Medical Association.
“If confirmed, this finding suggests that many cases of MS could be prevented by increasing vitamin D levels,” Ascherio said.
Still, he said the findings don’t prove that a lack of vitamin D can cause MS, so it’s too preliminary to recommend that people take vitamin D pills to avoid the disease.
Sources of vitamin D
Vitamin D also is found in fortified milk and oily fish, but it’s hard to get enough just from diet. Sunlight is the biggest source of vitamin D, which is needed for strong bones. Other studies have linked high levels of vitamin D in the blood to lower risks of a variety of cancers.
The MS researchers worked with the Army and Navy in analyzing blood samples of military personnel stored by the Department of Defense.
Military databases showed that 257 service men and women were diagnosed with MS between 1992 and 2004. The increased MS risk was especially strong in people who were younger than 20 when they entered the study. The researchers said that finding suggests that vitamin D exposure before adulthood could be particularly important.
Using blood samples to measure vitamin D levels “tends to nail it down in a much more reliable way” than studies that have relied on people’s memories of vitamin D exposure, said Dr. Nicholas LaRocca of the National Multiple Sclerosis Society.
MS is among the most common nerve disorders affecting young adults, mostly women. About 350,000 people in the United States and 2 million worldwide have MS, a chronic autoimmune disease in which the body attacks the fatty insulation that surrounds nerve fibers.
Avoiding the sun
Ascherio said there’s some evidence that its incidence is increasing in sunny regions including the South and West, possibly because people are avoiding the sun or using sunscreen to protect against skin cancer.
Some doctors think those practices also have contributed to vitamin D deficiencies in adolescents and young adults.
“There’s no question that vitamin D deficiency is an epidemic in the United States,” said Dr. William Finn, a vitamin D expert at the University of North Carolina at Chapel Hill. The MS study “is just one more reason to pay attention to it.”
MS symptoms vary but can be disabling and can include tingling pain in the arms and legs, fatigue and vision problems.
Doctors believe it is genetic and perhaps triggered in susceptible people by environmental causes, including possibly some viruses. Vitamin D deficiency could be another trigger.
It’s unclear how lack of vitamin D might contribute. In mouse experiments, the vitamin stimulated production of chemicals that fight an MS-like disease.
____________________________________________
Live Vote
Will this study cause you to change your diet or behavior in an attempt to help prevent multiple sclerosis? * 54 responses | |||||
Yes, I plan to start taking vitamin D supplements and eating more fish and fortified foods. 37% | |||||
Yes, this is exactly the excuse I need to take more tropical vacations! 5.6% | |||||
Yes, all of the above. 33% | |||||
I'm not sure what I'll do. I'd like to spend more time in the sun, but don't want to get skin cancer or wrinkles. 13% | |||||
No, I'm going to wait for more evidence about vitamin D. 11% | |||||
Not a scientific survey. Click to learn more. Results may not total 100% due to rounding. |
Uncertain Biogen Applying to Sell MS Drug for Crohn's RedNova Mon, 18 Dec 2006 10:05 AM PST By Jeffrey Krasner, The Boston Globe Dec. 16--Biogen Idec Inc. and Elan Corp. said yesterday that they have applied to the Food and Drug Administration for approval to sell Tysabri, a multiple sclerosis drug, to treat patients with Crohn's disease. |
Health calendar Gloucester Daily Times Mon, 18 Dec 2006 9:25 AM PST *Mondays, 10 to 11 a.m., Tai chi with Meredith Morgan. *Tuesdays, 9:45 to 11 a.m., Yoga with Mary Ann Wenniger. *Wednesdays, 12:30 to 1:30 p.m., Chair Yoga with Nana Dunn. |
Biogen wants approval of Tysabri for Crohn's disease
San Antonio Business Journal - San Antonio,
TX,USA ... Tysabri was cleared to return to
market in July, with restrictions, after previous
clinical data was reevaluated, giving Cambridge,
Mass.-based Biogen Idec and ...
Elan and Biogen Idec Submit Supplemental Biologics License ...
PharmaLive.com (press release) - Newtown,PA,USA
... of a supplemental Biologics License Application
(sBLA) to the US Food and Drug Administration
(FDA) seeking approval to market TYSABRI(R) (natalizumab) in the ...
UPDATE 1-Elan, Biogen jump on Crohn's filing for Tysabri
Reuters - USA
... and Biogen Idec on Friday said they asked
US regulators to approve use of their multiple
sclerosis drug Tysabri, which has been hurt by
safety concerns, to ...
Elan, Biogen seek Tysabri OK for Crohn's
United Press International - USA
15 (UPI) -- Irish firm Elan and US drug maker
Biogen Idec said Friday they are seeking approval
of multiple-sclerosis drug Tysabri for Crohn's
disease. ...
See all stories on this topic
Elan wants to use Tysabri to treat Crohn's
RTE.ie - Ireland
Elan Corporation and Biogen Idec said today that
they have asked US regulators to approve use of their
multiple sclerosis drug Tysabri, which has been
hounded ...